News Channels

20 Mar 2017 GeoVax Reports Promising Results for Zika Vaccine
20 Mar 2017 Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 3 and TONES 4 Studies of JZP-110 in Patients with Obstructive Sleep Apnea
20 Mar 2017 BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment
20 Mar 2017 Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001
20 Mar 2017 Opiant Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
20 Mar 2017 Neothetics Announces Last Subject Enrolled in Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat
20 Mar 2017 Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases
20 Mar 2017 X-Chem Announces Strategic Collaboration with Astellas Pharma Across Multiple Therapeutic Areas
20 Mar 2017 Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival
20 Mar 2017 Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody™ Therapeutics for the Treatment of Cancer and Other Diseases
20 Mar 2017 NightstaRx Commences first Phase I/II Gene Therapy Clinical Trial for Patients with X-Linked Retinitis Pigmentosa
20 Mar 2017 Lowering LDL Levels With Repatha® (Evolocumab) Did Not Adversely Affect Cognitive Function In Landmark Phase 3 Study
20 Mar 2017 AstraZeneca’s CVD-REAL study shows SGLT-2 inhibitors significantly reduced death and hospitalisations for heart failure versus other type-2 diabetes medicines
20 Mar 2017 Bayer’s Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study
18 Mar 2017 The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran
18 Mar 2017 AveXis Reports Topline Results from Phase 1 Trial of AVXS-101 in SMA Type 1 and Fourth Quarter and Full Year 2016 Financial and Operating Results
18 Mar 2017 Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues
17 Mar 2017 Nordic Nanovector Announces First Patient Dosed in Phase 1 Study of Betalutin® in Diffuse Large B-cell Lymphoma (DLBCL), an Aggressive Form of NHL
17 Mar 2017 Threshold Pharmaceuticals and Molecular Templates Agree to Combine
17 Mar 2017 First dedicated outcome trials of empagliflozin in chronic heart failure initiated

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top